Tag: Pharmacogenetics

Approximately 1 in 300 people have a complete deficiency of the thiopurine S-methyltransferase (TPMT) enzyme, putting them at high risk for severe drug toxicity. This article explains what is TPM in medicine by focusing on the crucial role of TPMT in personalizing treatment.

While stimulant medications are effective for 70% of adults with ADHD, some individuals find that a specific medication like Concerta doesn't work for them. So, what does it mean if Concerta has no effect? Several factors could be at play.

Approximately 3 to 5% of the population has a reduced function of the DPD enzyme, a condition known as DPD deficiency, which significantly increases the risk of severe toxicity from certain chemotherapy drugs. This fact highlights why it is critical to understand that the query 'What is the drug DPD?' is based on a fundamental misconception, as DPD refers to an enzyme, not a medication.

Genetic variations in the CYP2C19 enzyme can make clopidogrel less effective for some individuals, leaving them at higher risk for heart attacks and strokes. This variability has driven the development of more potent and predictable alternatives, prompting many to ask: is there a better alternative to clopidogrel? The answer, supported by clinical evidence, depends on balancing a patient's individual risk of clotting versus bleeding.

About 2% to 14% of Americans carry a genetic variation that prevents them from effectively converting clopidogrel into its active form, leading to a major **clopidogrel controversy** regarding its inconsistent efficacy. This issue, alongside concerns about drug-drug interactions and the emergence of more potent alternatives, has reshaped how the antiplatelet drug is prescribed and monitored.

Studies show that up to two-thirds of individuals with depression do not find relief from their first medication [1.4.2]. This highlights a major challenge in pharmacology that leads many to ask, 'What is Genomind Syrup used for?', seeking better solutions. The answer, however, is not in a bottle.

The U.S. Food and Drug Administration (FDA) has issued warnings linking fluoroquinolone antibiotics to an increased risk of aortic rupture or dissection, particularly in patients with connective tissue disorders like Ehlers-Danlos syndrome (EDS). Given the fragile nature of connective tissue in EDS, understanding which medications pose a risk is a critical part of a comprehensive management strategy.